Search

MSK gastroenterologist Robin Mendelsohn weighs in on the possible benefits and drawbacks of using aspirin to reduce the risk of colon and rectal cancer.

… Tuesday, March 21, 2017 Summary In this Q&A, MSK gastroenterologist Robin Mendelsohn weighs in on the possible benefits and drawbacks of using aspirin to reduce the risk of colon cancer and rectal cancer. Colorectal cancer is the third most common cancer in the United States for both men and women, excluding

Memorial Sloan Kettering Cancer Center (MSK) is the first academic research institution worldwide to join a major global initiative focused on revolutionizing clinical trial administration.

… Tuesday, December 17, 2024 Memorial Sloan Kettering Cancer Center (MSK) is the first academic research institution worldwide to join a major global initiative focused on revolutionizing clinical trial administration. The i-HD eSource Scale Up Task Force, led by the European Institute for Innovation through

Sloan Kettering Institute Structural Biology Program Chair Dr. Christopher Lima was elected to the 2025 class of American Association for the Advancement of Science Fellows.

… Tuesday, April 14, 2026 Christopher D. Lima, PhD , Chair of the Structural Biology Program at the Sloan Kettering Institute and a Howard Hughes Medical Institute Investigator was named a 2025 Honorary Fellow of the  American Association for the Advancement of Science  — one of the world’s largest scientific

Uterine-preserving surgery results in excellent and similar five-year disease-specific survival compared to hysterectomy in young women with stage IB1 cervical cancer.

… Monday, January 14, 2019 Uterine-preserving surgery results in excellent and similar five-year disease-specific survival compared to hysterectomy in young women with stage IB1 cervical cancer , especially in women with smaller tumors, according to our recent research. The retrospective study is one of

Treatment with chimeric antigen receptor T cell therapy should proceed in patients with B cell non-Hodgkin lymphomas and B cell acute lymphocytic leukemia, despite Covid-19 according to the CAR T Cell Consortium, a collaboration of investigators from eight U.S. academic institutions.

… Monday, May 11, 2020 Treatment with chimeric antigen receptor T cell therapy should proceed in patients with B cell non-Hodgkin lymphomas and B cell acute lymphocytic leukemia, despite the challenges of Covid-19, according to the CAR T Cell Consortium, a collaboration of investigators from eight U.S.

Our review summarizes recent developments in treatment planning and delivery, existing clinical evidence, and ongoing prospective trials in major head and neck cancers that may further increase the therapeutic window of proton therapy for patients with head and neck cancer.

… Tuesday, October 13, 2020 Proton beam radiation has distinct tissue-sparing advantages over conventional photon-based radiation, making it especially beneficial for treating localized head and neck cancers, which typically have complex anatomy and are located near vital organs. We recently published

MSK's Neil Iyengar will present at the American Association for Cancer Research special conference about the risk of invasive breast cancer. A new study found that the risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat. These findings suggest that having a normal BMI can provide false reassurance regarding the risk of breast cancer associated with body fat, and they also highlight the potential role of physical activity and exercise even in those who are at a normal weight. For expert interviews, please contact Nicole H. McNamara at [email protected].

… Friday, January 26, 2018 Bottom Line: The risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat, meaning that a large portion of the population has an unrecognized risk of developing cancer. In addition, a lower level of

Dr. Sawyers is recognized for his dedication to cancer research, education, collaboration, science policy, advocacy, and funding.

… Friday, April 9, 2021 Memorial Sloan Kettering (MSK) is proud to announce that Charles L. Sawyers, MD, FAACR , Chair of MSK’s Human Oncology and Pathogenesis Program (HOPP) and Howard Hughes Medical Institute Investigator, will receive the 2021 American Association for Cancer Research (AACR) Distinguished

Memorial Sloan Kettering Cancer Center announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with a state-of-the-art outpatient medical facility to be known as The David H. Koch Center for Cancer Care. The new center will provide the most advanced cancer treatments in a dynamic space designed with the needs of patients firmly in mind.

… Wednesday, May 20, 2015 Memorial Sloan Kettering Cancer Center (MSK) today announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with a state-of-the-art outpatient

During the COVID-19 pandemic, MSK doctors and researchers are applying their knowledge about immunology toward the development of treatments.

… Friday, May 15, 2020 Summary During the COVID-19 pandemic, MSK doctors and researchers are applying their knowledge about immunology toward the development of treatments. As leaders in immunotherapy, Memorial Sloan Kettering researchers have spent decades studying how the immune system responds to cancer